Stock Analysis, Dividends, Split History

SHLM / Schulman (A.), Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price43.60
Volume67,900.00
Market Cap ($M)1,305.02
Enterprise Value ($M)2,208.97
Book Value ($M)192.97
Book Value / Share6.54
Price / Book6.10
NCAV ($M)-725.14
NCAV / Share-24.57
Price / NCAV-1.77
Share Statistics
Common Shares Outstanding 29,499,905
Convertible Special Stock Shares Outstanding 125,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.02
Return on Equity (ROE)0.21
Balance Sheet (mrq) ($M)
Assets1,769.99
Liabilities1,566.47
Quick Ratio1.09
Current Ratio1.72
Income Statement (mra) ($M)
Sales Revenue Net2,461,124,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Operating Income85.80
Net Income34.17
Earnings Per Share Diluted0.86
Earnings Per Share Basic0.87
Cash Flow Statement (mra) ($M)
Cash From Operations104.72
Cash from Investing-32.22
Cash from Financing-32.22
Identifiers and Descriptors
CUSIP808194104
Central Index Key (CIK)87565
Related CUSIPS
808194904 808194954

Split History

Stock splits are used by Schulman (A.), Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

LyondellBasell Gets EU Antitrust Nod to A. Schulman Buyout

2018-06-28 zacks
Chemicals giant, LyondellBasell Industries N.V. (LYB - Free Report) has secured the antitrust approval from the European Commission for its proposed buyout of A. Schulman, Inc. (SHLM - Free Report) in a deal worth $2.25 billion. The clearance satisfies one of the closing conditions to the transaction. The deal now remains subject to other customary closing conditions including other required regulatory approvals. (26-0)

LyondellBasell (LYB) Up 44% in a Year: What's Driving It?

2018-06-11 zacks
Shares of LyondellBasell Industries N.V. (LYB - Free Report) have rallied around 44% over a year. The company has also outperformed its industry's gain of roughly 12% over the same time frame. LyondellBasell, a Zacks Rank #3 (Hold) stock, has a market cap of roughly $46.2 billion and average volume of shares traded in the last three months is around 2,446.6K. The company has expected long-term earnings per share growth of around 9%. (54-0)

LyondellBasell Gets China Antitrust Nod for A. Schulman Buy

2018-05-23 zacks
Chemicals giant, LyondellBasell Industries N.V. (LYB - Free Report) has secured the approval from the Chinese State Administration of Market Regulation ("SAMR") for its proposed buyout of A. Schulman, Inc. (SHLM - Free Report) in a deal worth $2.25 billion. The clearance satisfies one of the closing conditions to the transaction. The deal now remains subject to other customary closing conditions including approval by A. (28-0)

Rayonier Advanced Materials (RYAM) Catches Eye: Stock Jumps 8.5%

2018-03-28 zacks
Rayonier Advanced Materials Inc. (RYAM - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $19.32–$21.37 in the past one-month time frame, witnessed a sharp increase yesterday. (21-0)

LyondellBasell Gets U.S. Antitrust Nod for A. Schulman Buyout

2018-03-22 zacks
Chemicals giant LyondellBasell Industries N.V. (LYB - Free Report) has secured the U.S. antitrust clearance for its proposed buyout of A. Schulman, Inc. (SHLM - Free Report) in a deal worth $2.25 billion. The termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 satisfied one of the closing conditions to the transaction. The deal now remains subject to other customary closing conditions including approval by A. (25-0)

CUSIP: 808194104